» Articles » PMID: 39355029

The Application of Radionuclide Therapy for Breast Cancer

Overview
Journal Front Nucl Med
Date 2024 Oct 2
PMID 39355029
Authors
Affiliations
Soon will be listed here.
Abstract

Radionuclide-mediated diagnosis and therapy have emerged as effective and low-risk approaches to treating breast cancer. Compared to traditional anatomic imaging techniques, diagnostic radionuclide-based molecular imaging systems exhibit much greater sensitivity and ability to precisely illustrate the biodistribution and metabolic processes from a functional perspective in breast cancer; this transitions diagnosis from an invasive visualization to a noninvasive visualization, potentially ensuring earlier diagnosis and on-time treatment. Radionuclide therapy is a newly developed modality for the treatment of breast cancer in which radionuclides are delivered to tumors and/or tumor-associated targets either directly or using delivery vehicles. Radionuclide therapy has been proven to be eminently effective and to exhibit low toxicity when eliminating both primary tumors and metastases and even undetected tumors. In addition, the specific interaction between the surface modules of the delivery vehicles and the targets on the surface of tumor cells enables radionuclide targeting therapy, and this represents an exceptional potential for this treatment in breast cancer. This article reviews the development of radionuclide molecular imaging techniques that are currently employed for early breast cancer diagnosis and both the progress and challenges of radionuclide therapy employed in breast cancer treatment.

References
1.
Brechbiel M . Targeted α-Therapy. Cancer Biother Radiopharm. 2020; 35(6):397. DOI: 10.1089/cbr.2020.29008.mbr. View

2.
Filippi L, Bagni O, Nervi C . Aptamer-based technology for radionuclide targeted imaging and therapy: a promising weapon against cancer. Expert Rev Med Devices. 2020; 17(8):751-758. DOI: 10.1080/17434440.2020.1796633. View

3.
Yin G, Zeng B, Peng Z, Liu Y, Sun L, Liu C . Synthesis and application of 131I-fulvestrant as a targeted radiation drug for endocrine therapy in human breast cancer. Oncol Rep. 2018; 39(3):1215-1226. DOI: 10.3892/or.2018.6212. View

4.
Larson S, Carrasquillo J, Cheung N, Press O . Radioimmunotherapy of human tumours. Nat Rev Cancer. 2015; 15(6):347-60. PMC: 4798425. DOI: 10.1038/nrc3925. View

5.
Aide N, Heutte N, Rame J, Rousseau E, Loiseau C, Henry-Amar M . Clinical relevance of single-photon emission computed tomography/computed tomography of the neck and thorax in postablation (131)I scintigraphy for thyroid cancer. J Clin Endocrinol Metab. 2009; 94(6):2075-84. DOI: 10.1210/jc.2008-2313. View